Aurora CannabisACB -0.70%63 Days Payable is 426.93 as of Mar. 2026, which is 844% above its 10-year median of 45.24. GuruFocus rates ACB with a GF Score™ of 63/100 and a GF Value™ of $4.25 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 923 Drug Manufacturers companies, Aurora Cannabis ranks better than 52.11% on this metric.
The historical rank and industry rank for Aurora Cannabis's Days Payable or its related term are showing as below:
ACB'
s Days Payable Range Over the Past 10 Years
Min: 22.56 Med: 45.24 Max: 947.35
Current: 93.5
During the past 13 years, Aurora Cannabis's highest Days Payable was 947.35. The lowest was 22.56. And the median was 45.24.
ACB's Days Payable is ranked better than 52.11% of 923
companies
in the Drug Manufacturers industry
Industry Median: 90.98
vs ACB: 93.50
Aurora Cannabis's Days Payable
increased
from Mar. 2025 (171.65) to Mar. 2026 (426.93).
It may suggest that Aurora Cannabisdelayed paying its suppliers.
Aurora Cannabis Days Payable Related Terms
Aurora Cannabis Days Payable Historical Data
* Premium members only.
The historical data trend for Aurora Cannabis's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Aurora Cannabis's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aurora Cannabis Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aurora Cannabis's Days Payable distribution charts can be found below:
* The bar in red indicates where Aurora Cannabis's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Aurora Cannabis's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aurora Cannabis (ACB) has a Days Payable of 426.93 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Aurora Cannabis and its competitors. This is 844% above median its historical median of 45.24. Over the past decade, Aurora Cannabis' Days Payable has ranged from 22.56 to 947.35. According to the industry distribution chart, Aurora Cannabis ranks #442 out of 923 companies in the Drug Manufacturers industry, placing it in the top 47.9%.
Is Aurora Cannabis' Days Payable too high?
Aurora Cannabis' current Days Payable of 426.93 is 844% above median its 10-year median of 45.24. Over the past 10 years, this metric has ranged from a low of 22.56 to a high of 947.35. The Drug Manufacturers industry median Days Payable is 90.98. Aurora Cannabis' value of 426.93 is 369.3% above this industry median. Based on the distribution chart, Aurora Cannabis ranks #442 out of 923 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Aurora Cannabis has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Aurora Cannabis' Days Payable compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Aurora Cannabis ranks #442 out of 923 companies for Days Payable. This puts Aurora Cannabis in the upper half of its industry. The industry median Days Payable is 90.98. Aurora Cannabis' value of 426.93 is 369.3% above this benchmark. Historically, Aurora Cannabis' own Days Payable has ranged from 22.56 to 947.35 over the past decade. While the company's 10-year median is 45.24 vs. the industry median of 90.98, Aurora Cannabis has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.98, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aurora Cannabis's current Days Payable of 426.93 is 369.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Aurora Cannabis and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aurora Cannabis's current Days Payable is 426.93, which is 844% above median its own 10-year median of 45.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aurora Cannabis stock overvalued right now?
Based on GuruFocus' analysis, Aurora Cannabis (ACB) is currently considered Possible Value Trap. The stock's GF Value™ is $4.25, compared to a current price of $2.83 — trading 33.4% below its estimated fair value. The current Days Payable is 426.93, which is 844% above median its 10-year median of 45.24 and 369.3% above the Drug Manufacturers industry median of 90.98. Aurora Cannabis' overall GF Score™ is 63/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Aurora Cannabis (ACB), the current Days Payable is 426.93 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aurora Cannabis (ACB) Overvalued in 2026?
Based on GuruFocus' analysis, Aurora Cannabis stock appears to be undervalued.
The current stock price of $2.83 is trading 33.4% below its estimated GF Value™ of $4.25.
GuruFocus considers Aurora Cannabis to be Possible Value Trap.
Key valuation signals for ACB:
Days Payable: 426.93 (844% above median its 10-year median of 45.24)
GF Value™: $4.25 vs. price of $2.83 (33.4% below fair value)
Industry Position: 369.3% above the Drug Manufacturers median (#442 of 923)
No single metric tells the full story. See the ACB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aurora Cannabis Inc is focused on the production, distribution, and sale of cannabis products in Canada and internationally. The Company conducts the production, distribution, and sale of medical cannabis products and, on a very limited basis, consumer cannabis products in Canada pursuant to the Cannabis Act; the production and distribution of wholesale medical cannabis in the European Union pursuant to the German Medicinal Products Act and German Narcotic Drugs Act; and the distribution of wholesale medical cannabis in various international markets, including Australia and New Zealand. Its segments are Canadian Cannabis CGU, European Cannabis CGU, Australia Cannabis CGU, and New Zealand Cannabis CGU, with Canada generating majority revenue.
63GF Score
Get the complete analysis for ACB
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACB has been successfully added to your 
